{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:02:35Z","timestamp":1790794955903,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12185-025-04069-y","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:58:22Z","timestamp":1759395502000},"page":"233-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3780-5331","authenticated-orcid":false,"given":"Michihide","family":"Tokuhira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Senpuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Osada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Oshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"issue":"364","key":"4069_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"17","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;17(364):1046\u201360.","journal-title":"N Engl J Med"},{"key":"4069_CR2","unstructured":"International Myeloma Working Group (IMWG) guidelines. https:\/\/www.myeloma.org\/imwg-publications"},{"key":"4069_CR3","unstructured":"NCCN Clinical practice guidelines in oncology. Multiple Myeloma. Version 2.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"4069_CR4","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"4069_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/hematology.2024000580","volume":"6","author":"A Perrot","year":"2024","unstructured":"Perrot A. Transplant in myeloma: who, when, and why? Hematology Am Soc Hematol Educ Program. 2024;6:561\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4069_CR6","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/j.clml.2024.10.012","volume":"25","author":"S Khan","year":"2022","unstructured":"Khan S, Bergstrom DJ, C\u00f4t\u00e9 J, Kotb R, LeBlanc R, Louzada ML, et al. First line treatment of newly diagnosed transplant eligible multiple myeloma recommendations from a canadian consensus guideline consortium. Clin Lymphoma Myeloma Leuk. 2022;25:e151\u201372.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4069_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","volume":"15","author":"D Kegyes","year":"2022","unstructured":"Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient? J Hematol Oncol. 2022;15:78.","journal-title":"J Hematol Oncol"},{"key":"4069_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12185-022-03365-1","volume":"115","author":"K Ohmine","year":"2022","unstructured":"Ohmine K, Uchibori R. Novel immunotherapies in multiple myeloma. Int J Hematol. 2022;115:799\u2013810.","journal-title":"Int J Hematol"},{"key":"4069_CR9","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus Lenalidomide and Dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104\u201315.","journal-title":"N Engl J Med"},{"key":"4069_CR10","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219\u201326.","journal-title":"J Clin Oncol"},{"key":"4069_CR11","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/cncr.34760","volume":"129","author":"SJ Grant","year":"2023","unstructured":"Grant SJ, Wildes TM, Rosko AE, Silberstein J, Giri S. A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma. Cancer. 2023;129:2023\u201334.","journal-title":"Cancer"},{"key":"4069_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002305","volume":"94","author":"P Hsu","year":"2015","unstructured":"Hsu P, Lin TW, Gau JP, Yu YB, Hsiao LT, Tzeng CH, et al. Risk of early mortality in patients with newly diagnosed multiple myeloma. Medicine (Baltimore). 2015;94:e2305.","journal-title":"Medicine (Baltimore)"},{"key":"4069_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/10245332.2015.1101969","volume":"21","author":"YK Chen","year":"2016","unstructured":"Chen YK, Han SM, Yang Y, Lin TH, Tzeng HE, Chang KH, et al. Early mortality in multiple myeloma: experiences from a single institution. Hematology. 2016;21:392\u20138.","journal-title":"Hematology"},{"key":"4069_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/ajh.24796","volume":"92","author":"H Terebelo","year":"2017","unstructured":"Terebelo H, Srinivasan S, Narang M, Abonour R, Gasparetto C, Toomey K, et al. Recognition of early mortality in multiple myeloma by a prediction matrix. Am J Hematol. 2017;92:915\u201323.","journal-title":"Am J Hematol"},{"issue":"1","key":"4069_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1186\/s12885-016-2645-y","volume":"16","author":"SH Jung","year":"2016","unstructured":"Jung SH, Cho MS, Kim HK, Kim SJ, Kim K, Cheong JW, et al. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. BMC Cancer. 2016;16(1):613.","journal-title":"BMC Cancer"},{"key":"4069_CR16","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1177\/0300060518757640","volume":"46","author":"J Xia","year":"2018","unstructured":"Xia J, Wang L, Zhou X, Wang J, Wang H, Guo H. Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice. J Int Med Res. 2018;46:2230\u20137.","journal-title":"J Int Med Res"},{"key":"4069_CR17","first-page":"527","volume":"131","author":"G Charli\u0144ski","year":"2021","unstructured":"Charli\u0144ski G, Tyczy\u0144ska A, Ma\u0142ecki B, Fornagiel S, Barchnicka A, Ko\u0142kowska A, et al. Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a \u201creal-world\u201d study: experiences of the Polish Myeloma Group. Pol Arch Intern Med. 2021;131:527\u201334.","journal-title":"Pol Arch Intern Med"},{"key":"4069_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical stat1stics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"4069_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/jcm10010105","volume":"10","author":"K Akizuki","year":"2020","unstructured":"Akizuki K, Matsuoka H, Toyama T, Kamiunten A, Sekine M, Shide K, et al. Real-world data on clinical features, outcomes, and prognostic factors in multiple myeloma from Miyazaki Prefecture, Japan. J Clin Med. 2020;10:105.","journal-title":"J Clin Med"},{"key":"4069_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s12185-023-03653-4","volume":"118","author":"Y Shimura","year":"2023","unstructured":"Shimura Y, Shibayama H, Nakaya A, Yamamura R, Imada K, Kaneko H, et al. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum. Int J Hematol. 2023;118:609\u201317.","journal-title":"Int J Hematol"},{"issue":"Suppl 2","key":"4069_CR21","first-page":"S46","volume":"98","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Kumar S. Prevention of infections including vaccination strategies in multiple myeloma. Am J Hematol. 2023;98(Suppl 2):S46\u201362.","journal-title":"Am J Hematol"},{"issue":"5","key":"4069_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41408-021-00490-8","volume":"11","author":"N Puig","year":"2021","unstructured":"Puig N, Hern\u00e1ndez MT, Rosi\u00f1ol L, Gonz\u00e1lez E, de Arriba F, Oriol A, et al. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer J. 2021;11(5):101.","journal-title":"Blood Cancer J"},{"key":"4069_CR23","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/leu.2012.124","volume":"26","author":"DH Vesole","year":"2012","unstructured":"Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus S, et al. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study. Leukemia. 2012;26:2517\u201320.","journal-title":"Leukemia"},{"key":"4069_CR24","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143\u201361.","journal-title":"Lancet Haematol"},{"key":"4069_CR25","doi-asserted-by":"publisher","first-page":"101287","DOI":"10.1016\/j.blre.2025.101287","volume":"11","author":"A Kannan","year":"2025","unstructured":"Kannan A, Jeffrey K, Misbah S, Ramasamy K. Practical guidance on the prevention and management of infection in multiple myeloma patients: a case-based approach. Ramasamy K Blood Rev. 2025;11:101287.","journal-title":"Ramasamy K Blood Rev"},{"key":"4069_CR26","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1182\/blood.V120.21.2916.2916","volume":"120","author":"K Kistler","year":"2012","unstructured":"Kistler K, Rajangam K, Faich GSL. Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice. Blood. 2012;120:2916.","journal-title":"Blood"},{"key":"4069_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/bjh.14058","volume":"174","author":"D Robinson Jr","year":"2016","unstructured":"Robinson D Jr, Esseltine DL, Regnault A, Meunier J, Liu K, van de Velde H. The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials. Br J Haematol. 2016;174:368\u201381.","journal-title":"Br J Haematol"},{"key":"4069_CR28","first-page":"1518","volume":"13","author":"R R\u00edos-Tamayo","year":"2023","unstructured":"R\u00edos-Tamayo R, Krsnik I, G\u00f3mez-Bueno M, Garcia-Pavia P, Segovia-Cubero J, Huerta A, et al. AL amyloidosis and multiple myeloma: a complex scenario in which cardiac involvement remains the key prognostic factor. Life (Basel). 2023;13:1518.","journal-title":"Life (Basel)"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04069-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04069-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04069-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:50:44Z","timestamp":1771339844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04069-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4069"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04069-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.T received honoraria and speaker fees from Janssen Pharmaceutical, Bristol Myers Squibb, AbbVie GK, Towa Pharmaceutical, Chugai Pharmaceutical and Sanofi. H.N received honoraria and speaker fees from Janssen Pharmaceutical and Sanofi. K.T received honoraria and speaker fees from Novartis Pharma, AbbVie GK, Chugai Pharmaceutical, Sanofi, Ohara Pharmaceutical and AstraZeneca K.K. N.I received honoraria and speaker fees from Novartis Pharma, Pfizer, Ono Pharmaceutical, Otsuka Pharmaceutical, AbbVie GK, Nippon Shinyaku, Chugai Pharmaceutical, Janssen Pharmaceutical, Meiji Seika Pharma, and Asahi KASEI Pharma. A.T received honoraria and speaker fees from Janssen Pharmaceutical, Bristol Myers Squibb and Sanofi. E.S received honoraria and speaker fees from Janssen Pharmaceutical, Pfizer, Ono Pharmaceutica, Sanofi, Takeda Pharmaceutical Company, and Daiichi Sankyo Company. Y.A received honoraria and speaker fees from Janssen Pharmaceutical. J.Y received honoraria and speaker fees from Janssen Pharmaceutical, Sanofi, Bristol Myers Squibb, Pfizer, Fujimoto Pharmaceutical, Ono Pharmaceutic, and Takaeda Pharmaceutical. T.Y received honoraria and speaker fees from Janssen Pharmaceutical, Sanofi, Bristol Myers Squibb, and Ono Pharmaceutical.Y.S received honoraria and speaker fees from Chugai Pharmaceutical and AbbVie GK. G.O received honoraria and speaker fees from Janssen Pharmaceutical KK, Bristol Myers Squibb, Takeda Pharmaceutical, Pfizer, Ono Pharmaceutical, Chugai Pharmaceutical, Sanofi, and Towa Pharmaceutical Y.N received honoraria and speaker fees from Chugai Pharmaceutical, Janssen Pharmaceutical, Sanofi, Novartis Pharma, Ono Pharmaceutical, AbbVie GK, Takeda Pharmaceutical, Asahi Kasei Pharma Corporation, AstraZeneca K.K and Daiichi Sankyo Company. K.S received honoraria and speaker fees from Bristol Myers Squibb, Novartis Pharma, Takeda Pharmaceutical and Ono Pharmaceutical. T.K received honoraria and speaker fees from Janssen Pharmaceutical KK, Bristol Myers Squibb, Novartis Pharma, Takeda Pharmaceutical, Pfizer, Ono Pharmaceutical and Chugai Pharmaceutical and received research Fund from Chugai Pharmaceutical. K.M received honoraria and speaker fees from Chugai Pharmaceutical, Janssen Pharmaceutical, Nippon Shinyaku, AstraZeneca, AbbVie GK, Daiichi Sankyo, Kyowa Kirin, Novartis Pharma, Takeda Pharmaceuticals, Ono Pharmaceutical, and Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of each institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}